How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink

After years of layoffs, cash burn and political attacks on its core technology, Moderna's melanoma vaccine data notched the biotech company a much-needed win.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。